Amgen Boosts Forecast as Blockbuster Sales Exceed Expectations

Amgen Inc., a leading biotech firm, has raised its full-year profit and revenue forecast after exceeding Wall Street's expectations in sales of its key medicines. The company now expects annual sales to reach $38.2 billion to $39.4 billion, surpassing its previous guidance of $37.1 billion to $38.5 billion.

This upward revision is a testament to the success of Amgen's key products on the market. On an adjusted basis, the company expects annual profits in the range of $22.30 to $23.50 per share, indicating a significant increase from previous estimates.